Carita et al. demonstrated therapeutic efficacy for combination of PKC/mTOR inhibitors with PKC/p53-MDM2 inhibitors or mTORC1 inhibitors, both of which resulted in tumour regression in PDX mouse models by targeting the PKC pathway downstream of GNAQ and GNA11 driver mutations 56. The gene discussed is TP53; the disease is neoplasm.